Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Aphton |
---|---|
Information provided by: | Aphton |
ClinicalTrials.gov Identifier: | NCT00042510 |
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.
Condition | Intervention | Phase |
---|---|---|
Stomach Neoplasms Esophageal Neoplasms |
Drug: G17DT Immunogen |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Study ID Numbers: | GC4 |
Study First Received: | July 31, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00042510 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Gastroesophageal cancer Gastric cancer |
Stomach Diseases Digestive System Diseases Digestive System Neoplasms Esophageal Disorder Gastrointestinal Diseases Head and Neck Neoplasms |
Stomach Neoplasms Esophageal Neoplasms Gastrointestinal Neoplasms Esophageal Cancer Stomach Cancer Esophageal Diseases |
Neoplasms Stomach Diseases Digestive System Diseases Neoplasms by Site Digestive System Neoplasms Gastrointestinal Diseases |
Head and Neck Neoplasms Stomach Neoplasms Esophageal Neoplasms Gastrointestinal Neoplasms Esophageal Diseases |